ReviewJournal of immunology (Baltimore, Md. : 1950)2014
Type I interferon in the pathogenesis of lupus.
Review in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 326 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
326 citing papers in PubMed, 9 syntheses or guidelines pooled it, 556 citations in OpenAlex.
- Factors Associated with Systemic Lupus Erythematosus-Associated Interstitial Lung Disease and Clinical Outcomes: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Long-Term Safety and Efficacy of Anifrolumab in Systemic Lupus Erythematosus: A Meta-Analysis of Randomized Controlled Trials, Extension Studies, and Real-World Cohorts.Pharmacology · 2026Pooled it
- Systematic review of culture-confirmed septic pericarditis in systemic lupus erythematosus with an index case.Lupus science & medicine · 2026Pooled it
- Risk factors for pulmonary complications in systemic lupus erythematosus: a meta-analysis of infectious pneumonia and interstitial lung disease.Frontiers in immunology · 2026Pooled it
- Exercise and physical activity for fatigue, disease activity and immune-inflammatory outcomes in adults with systemic lupus erythematosus: an umbrella review.Frontiers in immunology · 2026Pooled it
- Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Saudi National Clinical Practice Guidelines for Management of Adult Systemic Lupus Erythematosus.Current rheumatology reviews · 2025Guideline
- Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.Frontiers in immunology · 2022Pooled it
- Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials.Zeitschrift fur Rheumatologie · 2021Pooled it
- The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2021Trial
- Contribution of localmBio · 2026Article
- Gut metaproteomics reveals activated arginine catabolism and impaired arginine biosynthesis in systemic lupus erythematosus.mSystems · 2026Article
- Increased group 2 Innate lymphoid cell (ILC2) activity in pediatric familial mediterranean fever patients with spondyloarthropathy.Clinical and experimental medicine · 2026Article
- TYK2 signaling as a molecular bridge between cytokine storm and chronic inflammation: therapeutic implications of deucravacitinib.Molecular biology reports · 2026Review
- Potential of chimeric antigen receptor (CAR) T cell immunotherapy in systemic lupus erythematosus (SLE).Clinical rheumatology · 2026Review
- Type I interferons enhance B cell activation and promote differentiation of double negative 2 cells in SLE.Lupus science & medicine · 2026Article
- Interferon-induced protein 44-like promoter Hypomethylation as an epigenetic hallmark of systemic lupus erythematosus.Journal of translational medicine · 2026Article
- From Genes to Pathways: The Molecular Landscape of Systemic Lupus Erythematosus.International journal of molecular sciences · 2026Review
- Immunometabolic remodeling of perivascular adipose tissue in murine lupus: implications for lupus vasculopathy.bioRxiv : the preprint server for biology · 2026Article
- Pathogenesis and therapeutic strategies for neuropsychiatric lupus centered on innate immune activation.Human cell · 2026Review
266 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Investigations of patients with systemic lupus erythematosus have applied insights from studies of the innate immune response to define IFN-I, with IFN-α as the dominant mediator, as central to the pathogenesis of this prototype systemic autoimmune disease. Genetic association data identify regulators of nucleic acid degradation and components of TLR-independent, endosomal TLR-dependent, and IFN-I-signaling pathways as contributors to lupus disease susceptibility. Together with a gene expression signature characterized by IFN-I-induced gene transcripts in lupus blood and tissue, those data support the conclusion that many of the immunologic and pathologic features of this disease are a consequence of a persistent self-directed immune reaction driven by IFN-I and mimicking a sustained antivirus response. This expanding knowledge of the role of IFN-I and the innate immune response suggests candidate therapeutic targets that are being tested in lupus patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.